On December 18, 2025, Mirum Pharmaceuticals, Inc. secured an agreement to sell 1,000,000 shares of common stock to TCG Crossover Management for approximately $68.48 million as part of a private investment in public equity (PIPE) deal, contingent on the pending merger closure.